An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
2021
Yan Guo | Wenhui He | Huihui Mou | Lizhou Zhang | Jing Chang | Shoujiao Peng | Amrita Ojha | Rubens Tavora | Mark S. Parcells | Guangxiang Luo | Wenhui Li | Guocai Zhong | Hyeryun Choe | Michael Farzan | Brian D. Quinlan
All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD).
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
